Bausch & Lomb Corp (BLCO) — Inside-Filings

Sentiment-Signal

31,1

Bearisch

Composite Score (0–100)

Insider (25%)

83.7

9 Insider, 1,2M $ Volumen

Institutionell (22,5%)

Keine neuen Positionen

Aktivist (12,5%)

Kein 13D/13G

Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)

Score-Verlauf (90 Tage)

Kritische 8-K Meldungen

Datum	Meldung	Schwere	Filing	Auszug
22.12.2025	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	o Section 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appo
18.08.2025	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	on Agreement was effective as of August 14, 2025. Item 5.02 Departure of Directors or Certain Officers; Election of Dire
23.07.2025	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
07.11.2023	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	+ Lomb Corporation Inc. (the “Company”) under Item 5.02 and 9.01 on June 1, 2023 (the “Original Form 8-K”) reporting tha
29.08.2023	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	+ Lomb Corporation Inc. (the “Company”) under Item 5.02 and 9.01 on April 12, 2023 (the “Original Form 8-K”) reporting t
01.06.2023	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co
12.04.2023	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;

Stammdaten

Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.

Unternehmen & Branche

Name	Bausch & Lomb Corp
Ticker	BLCO
CIK	0001860742
Boerse	US
Sektor	Healthcare
Industrie	Medical - Instruments & Supplies
SIC	3851 · Ophthalmic Goods

Wertpapier & Kennzahlen

CUSIP	–
ISIN	–
Typ	Common Stock
Marktkapitalisierung	5,52 Mrd. USD
Beta	0,65
Dividendenrendite	0,00 %

Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »

Finanzkennzahlen (SEC XBRL)

Periode	Filing	Umsatz	Nettoergebnis	EPS	Aktiva	Eigenkapital
2025-12-31	10-K	5,101,000,000	-360,000,000	-1.02	14,022,000,000	6,448,000,000
2025-09-30	10-Q	1,281,000,000	-28,000,000	-0.08	13,832,000,000	6,429,000,000
2025-06-30	10-Q	1,278,000,000	-62,000,000	-0.18	13,832,000,000	6,440,000,000
2025-03-31	10-Q	1,137,000,000	-212,000,000	-0.60	13,428,000,000	6,361,000,000
2024-12-31	10-K	4,791,000,000	-317,000,000	-0.90	13,469,000,000	6,473,000,000
2024-09-30	10-Q	1,196,000,000	4,000,000	0.01	13,515,000,000	6,589,000,000
2024-06-30	10-Q	1,216,000,000	-151,000,000	-0.43	13,250,000,000	6,504,000,000
2024-03-31	10-Q	1,099,000,000	-167,000,000	-0.48	13,293,000,000	6,659,000,000
2023-12-31	10-K	4,146,000,000	-260,000,000	-0.74	13,442,000,000	6,850,000,000
2023-09-30	10-Q	1,007,000,000	-84,000,000	-0.24	13,068,000,000	6,817,000,000
2023-06-30	10-Q	1,035,000,000	-32,000,000	-0.09	11,315,000,000	6,958,000,000
2023-03-31	10-Q	931,000,000	-90,000,000	-0.26	11,169,000,000	6,983,000,000
2022-12-31	10-K	3,768,000,000	6,000,000	0.02	11,144,000,000	7,033,000,000
2022-09-30	10-Q	942,000,000	-18,000,000	-0.05	10,696,000,000	6,729,000,000
2022-06-30	10-Q	941,000,000	5,000,000	0.01	11,002,000,000	6,896,000,000
2022-03-31	10-Q	889,000,000	20,000,000	0.06	10,907,000,000	7,140,000,000
2021-12-31	10-K	3,765,000,000	182,000,000	0.52	10,823,000,000	9,329,000,000
2021-09-30	10-Q	949,000,000	60,000,000	0.17
2021-06-30	10-Q	934,000,000	44,000,000	0.13
2021-03-31	10-Q	881,000,000	27,000,000	0.08

Fondsaktivität (Vorquartalsvergleich)

Keine Fondsdaten für dieses Unternehmen vorhanden.

Insider-Transaktionen (12 Monate)

Datum	Insider	Rolle	Typ	Stückzahl	Kurs	Wert (USD)	Δ
2026-03-06	Eldessouky Sam	Officer, EVP and CFO	Open Market Purchase	4,000	17.13	68,520.00	+50,5%
2026-03-06	Bailey A Robert D	Officer, EVP & Chief Legal Officer	Open Market Purchase	14,600	17.15	250,331.60	+184,5%
2026-03-06	SAUNDERS BRENT L	Director, Officer, CEO and Chairman of the Board	Open Market Purchase	14,700	17.14	251,958.00	+185,7%
2026-03-03	Ross Thomas W. Sr.	Director	Open Market Purchase	4,500	17.68	79,555.50	+58,6%
2026-03-02	Alfonso Eduardo	Director	Open Market Purchase	4,300	17.90	76,970.00	+56,7%
2026-02-27	VON ESCHENBACH ANDREW C.	Director	Open Market Purchase	4,364	18.31	79,883.02	+58,9%
2026-02-23	COLLIS STEVEN H	Director	Open Market Purchase	15,000	17.81	267,150.00	+196,9%
2026-02-20	ROBERTSON RUSSEL C	Director	Open Market Purchase	4,400	17.90	78,760.00	+58,1%
2026-02-19	Ling Karen	Director	Open Market Purchase	4,000	17.74	70,968.00	+52,3%
2025-05-22	SAUNDERS BRENT L	Director, Officer, CEO and Chairman of the Board	Open Market Purchase	22,000	11.28	248,072.00	+182,9%
2025-05-02	VON ESCHENBACH ANDREW C.	Director	Open Market Purchase	1,695	11.76	19,924.73	+14,7%

Top-Fondshalter

Keine Fondsdaten zu dieser Aktie vorhanden.